联邦制药现涨超5% 近日UBT251注射液慢性肾脏病适应症获临床试验默示许可

新浪港股02-06

热点栏目自选股数据中心行情中心资金流向模拟交易客户端　　联邦制药（03933）股价上涨5.27%，现报12.38港元，成交额2814.44万港元。　　消息面上，联邦制药发布公告，于2025年1月20日，公司全资附属公司联邦生物科技（珠海横琴）有限公司自主研发的1类创新药UBT251注射液关于慢性肾脏病适应症的Ⅱ期临床试验注册申请获得中国国家药品监督管理局临床试验默示许可。 ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2509298815?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-06 09:55","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2509298815","market":"hk","top_or_hot":-1,"title":"联邦制药现涨超5% 近日UBT251注射液慢性肾脏病适应症获临床试验默示许可","media":"新浪港股","content":"<div>\n<p>热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　联邦制药（03933）股价上涨5.27%，现报12.38港元，成交额2814.44万港元。\n　　消息面上，联邦制药发布公告，于2025年1月20日，公司全资附属公司联邦生物科技（珠海横琴）有限公司自主研发的1类创新药UBT251注射液关于慢性肾脏病适应症的Ⅱ期临床试验注册申请获得中国国家药品监督管理局临床试验默示许可。\n...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-06/doc-ineiparh1844940.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>联邦制药现涨超5% 近日UBT251注射液慢性肾脏病适应症获临床试验默示许可</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n联邦制药现涨超5% 近日UBT251注射液慢性肾脏病适应症获临床试验默示许可\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-06 09:55 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-06/doc-ineiparh1844940.shtml><strong>新浪港股</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　联邦制药（03933）股价上涨5.27%，现报12.38港元，成交额2814.44万港元。\n　　消息面上，联邦制药发布公告，于2025年1月20日，公司全资附属公司联邦生物科技（珠海横琴）有限公司自主研发的1类创新药UBT251注射液关于慢性肾脏病适应症的Ⅱ期临床试验注册申请获得中国国家药品监督管理局临床试验默示许可。\n...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-06/doc-ineiparh1844940.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1576","symbol_name":"医药外包概念","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-06/doc-ineiparh1844940.shtml","article_id":"2509298815","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2509298815","pubTimestamp":1738806900,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　联邦制药（03933）股价上涨5.27%，现报12.38港元，成交额2814.44万港元。\n　　消息面上，联邦制药发布公告，于2025年1月20日，公司全资附属公司联邦生物科技（珠海横琴）有限公司自主研发的1类创新药UBT251注射液关于慢性肾脏病适应症的Ⅱ期临床试验注册申请获得中国国家药品监督管理局临床试验默示许可。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1576":"医药外包概念","03933":"联邦制药","BK1141":"生命科学工具和服务","BK1191":"制药","03347":"泰格医药","BK1583":"高瓴概念"},"translate_title":"United Laboratories is now up more than 5%. Recently, UBT251 injection for chronic kidney disease indications received implied approval for clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03347":1,"03933":1},"content_text":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　联邦制药（03933）股价上涨5.27%，现报12.38港元，成交额2814.44万港元。\n　　消息面上，联邦制药发布公告，于2025年1月20日，公司全资附属公司联邦生物科技（珠海横琴）有限公司自主研发的1类创新药UBT251注射液关于慢性肾脏病适应症的Ⅱ期临床试验注册申请获得中国国家药品监督管理局临床试验默示许可。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.7","shortVersion":"4.31.7","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2509298815"}